MX368876B - Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1). - Google Patents

Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).

Info

Publication number
MX368876B
MX368876B MX2015007540A MX2015007540A MX368876B MX 368876 B MX368876 B MX 368876B MX 2015007540 A MX2015007540 A MX 2015007540A MX 2015007540 A MX2015007540 A MX 2015007540A MX 368876 B MX368876 B MX 368876B
Authority
MX
Mexico
Prior art keywords
lfa
inhibitor formulations
compound
formula
treatment
Prior art date
Application number
MX2015007540A
Other languages
English (en)
Other versions
MX2015007540A (es
Inventor
Newman Mary
Hunke William
Original Assignee
Sarcode Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50979140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX368876(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sarcode Bioscience Inc filed Critical Sarcode Bioscience Inc
Publication of MX2015007540A publication Critical patent/MX2015007540A/es
Publication of MX368876B publication Critical patent/MX368876B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formulaciones, métodos y kits para el tratamiento de enfermedades del ojo seco. En particular, las composiciones farmacéuticas estabilizadas que comprenden el compuesto de Fórmula I son descritas en la presente para una variedad de usos que incluyen, el tratamiento del síndrome del ojo seco. En un aspecto, se describen métodos e ingredientes para mejorar la estabilidad de composiciones del compuesto de Fórmula I.
MX2015007540A 2012-12-19 2013-12-18 Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1). MX368876B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261739609P 2012-12-19 2012-12-19
US201361758147P 2013-01-29 2013-01-29
PCT/US2013/076041 WO2014100135A1 (en) 2012-12-19 2013-12-18 Lfa-1 inhibitor formulations

Publications (2)

Publication Number Publication Date
MX2015007540A MX2015007540A (es) 2016-04-13
MX368876B true MX368876B (es) 2019-10-21

Family

ID=50979140

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015007540A MX368876B (es) 2012-12-19 2013-12-18 Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).
MX2019012375A MX2019012375A (es) 2012-12-19 2015-06-12 Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019012375A MX2019012375A (es) 2012-12-19 2015-06-12 Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).

Country Status (21)

Country Link
US (2) US11058677B2 (es)
EP (2) EP3827823A1 (es)
JP (1) JP6373867B2 (es)
KR (1) KR101891144B1 (es)
CN (1) CN104955453B (es)
AU (1) AU2013361579B2 (es)
BR (1) BR112015014367B1 (es)
CA (1) CA2894170C (es)
DK (1) DK2934510T3 (es)
EA (2) EA028008B1 (es)
ES (1) ES2846724T3 (es)
HK (2) HK1214536A1 (es)
HU (1) HUE052299T2 (es)
IL (1) IL239490B (es)
MX (2) MX368876B (es)
NZ (1) NZ708821A (es)
PL (1) PL2934510T3 (es)
PT (1) PT2934510T (es)
SI (1) SI2934510T1 (es)
WO (1) WO2014100135A1 (es)
ZA (2) ZA201504404B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995439B (zh) * 2016-01-26 2019-09-20 镇江圣安医药有限公司 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途
WO2019171260A1 (en) * 2018-03-09 2019-09-12 Mankind Pharma Ltd. Pharmaceutical composition of lifitegrast
CN114025759A (zh) * 2019-04-18 2022-02-08 阿祖拉眼科有限公司 用于治疗眼病的化合物和方法
EP3842032A1 (en) 2019-12-24 2021-06-30 Warszawskie Zaklady Farmaceutyczne Polfa S.A. A pharmaceutical formulation
KR20240109779A (ko) * 2023-01-05 2024-07-12 주식회사 종근당 리피테그라스트와 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2694719A (en) 1949-02-12 1954-11-16 Opplt Jan Method of stabilizing ascorbic acid with alkali-thiosulfate-carbamide-complexes
DK0642332T3 (da) * 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmiske præparater indeholdende cyclosporin
US5429819A (en) * 1992-10-14 1995-07-04 Matsushita Electric Industrial Co., Ltd. Antiviral composition
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
RU2149611C1 (ru) * 1998-04-06 2000-05-27 Московская медицинская академия им. И.М. Сеченова Капли для лечения воспалительных заболеваний глаз (варианты)
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
US8877168B1 (en) * 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
FI119361B (fi) 2003-09-26 2008-10-31 Raute Oyj Menetelmä viilun sorvaamiseksi
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
SI1881823T1 (sl) * 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
US8101654B2 (en) * 2005-07-08 2012-01-24 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising olopatadine
US7544893B2 (en) 2007-07-25 2009-06-09 Thomas & Betts International, Inc. Extruded wire duct end cap
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
US8080562B2 (en) * 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
ES2763703T3 (es) 2008-04-15 2020-05-29 Sarcode Bioscience Inc Antagonistas de LFA-1 tópicos utilizados en el tratamiento localizado de trastornos inmunes
CA2737475A1 (en) * 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
WO2010070664A1 (en) * 2008-11-17 2010-06-24 Laila Pharmaceuticals Pvt. Ltd. Curcuminoids and its metabolites for the application in ocular diseases
AU2009347921B8 (en) * 2009-06-10 2014-07-24 Mitotech Sa Pharmaceutical composition for use in medical and veterinary ophthalmology
KR20110001103A (ko) * 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
BR112012012387A2 (pt) * 2009-11-23 2019-09-24 Allergan Inc 7-[3,5-di-hidroxi-5-fenil-pent-1-enil)-ciclopentil]-n-etil-hept-5-enamida (bimatoprost) na forma cristalina ii, métodos para a preparação e métodos de utilização da mesma
US20120190653A1 (en) * 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
EP2675455A4 (en) * 2011-02-18 2014-07-16 M S Appasamy Associates OPHTHALMIC COMPOSITION FOR DILATING PUPILS
KR20140074881A (ko) * 2011-06-29 2014-06-18 알러간, 인코포레이티드 두드러기의 치료에서 이용을 위한 알카프타딘
EP2830627B1 (en) * 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
CN103230583A (zh) * 2013-05-17 2013-08-07 江西省创欣药业集团有限公司 兽用治疗肠道疾病的烟酸诺氟沙星复方注射液及制备方法

Also Published As

Publication number Publication date
MX2019012375A (es) 2020-01-20
KR20150100763A (ko) 2015-09-02
EA201791321A1 (ru) 2018-04-30
IL239490A0 (en) 2015-08-31
JP2016503058A (ja) 2016-02-01
EP3827823A1 (en) 2021-06-02
NZ708821A (en) 2020-03-27
HUE052299T2 (hu) 2021-04-28
US20150320737A1 (en) 2015-11-12
SI2934510T1 (sl) 2021-02-26
ZA201608069B (en) 2017-11-29
JP6373867B2 (ja) 2018-08-15
EA201591180A1 (ru) 2015-12-30
HK1214536A1 (zh) 2016-07-29
CA2894170C (en) 2021-08-10
US20220000859A1 (en) 2022-01-06
WO2014100135A1 (en) 2014-06-26
EP2934510B1 (en) 2020-10-28
EA028008B1 (ru) 2017-09-29
AU2013361579B2 (en) 2018-05-24
EP2934510A1 (en) 2015-10-28
PT2934510T (pt) 2021-01-13
AU2013361579A1 (en) 2015-06-18
US11058677B2 (en) 2021-07-13
IL239490B (en) 2018-12-31
EP2934510A4 (en) 2016-08-17
ES2846724T3 (es) 2021-07-29
MX2015007540A (es) 2016-04-13
KR101891144B1 (ko) 2018-08-23
DK2934510T3 (da) 2021-01-25
PL2934510T3 (pl) 2021-07-05
ZA201504404B (en) 2020-01-29
CN104955453B (zh) 2018-09-18
BR112015014367B1 (pt) 2022-11-22
CA2894170A1 (en) 2014-06-26
CN104955453A (zh) 2015-09-30
HK1214963A1 (zh) 2016-08-12
BR112015014367A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
MX2018015892A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
CA2871471C (en) Dna-pk inhibitors
WO2014097151A3 (en) Autotaxin inhibitors
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
PH12016501807A1 (en) Novel compounds
EA201490846A1 (ru) Новые производные арилхинолина
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
SG10201907289VA (en) Monomethylfumarate prodrug compositions
PH12020550494A1 (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
UA113540C2 (xx) Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду
MX359955B (es) Formulación de aroma y fragancia (iii).
MX2015004316A (es) Formulacion de aroma y fragancia (iv).
WO2013040535A3 (en) Bicarbocyclic and tricarbocyclic ethynyl derivatives and uses of same
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز
MA39762A (fr) Nouveaux composés

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration